Evidence map›Paper›PMID 36831286›Full record

ArticleCells2023

Complementary Cell Lines for Protease Gene-Deleted Single-Cycle Adenovirus Vectors.

Seyyed Mehdy Elahi, Nazila Nazemi-Moghaddam, Claire Guilbault, Mélanie Simoneau, Rénald Gilbert

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Seyyed Mehdy ElahiDepartment of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada.ORCID 0000-0003-2040-5665
Nazila Nazemi-MoghaddamDepartment of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada.
Claire GuilbaultDepartment of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada.
Mélanie SimoneauDepartment of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada.
Rénald GilbertDepartment of Production Platforms & Analytics, National Research Council Canada, Building Montreal, Montreal, QC H4P 2R2, Canada.
National Research Council Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To increase the safety of adenovirus vector (AdV)-based therapy without reducing its efficacy, a single-cycle adenovirus vector (SC-AdV) with a deletion in the protease gene (PS) was developed in order to be used as a substitute for the replication-competent adenovirus (RC-AdV). Since no infectious viral particles are assembled, there is no risk of viral shedding. The complementary cell lines for this developed AdV proved to be suboptimal for the production of viral particles and require the presence of fetal bovine serum (FBS) to grow. In the current study, we produced both stable pools and clones using adherent and suspension cells expressing the PS gene. The best adherent cell pool can be used in the early stages for the generation of protease-deleted adenovirus, plaque purification, and titration. Using this, we produced over 3400 infectious viral particles per cell. Additionally, the best suspension subclone that was cultured in the absence of FBS yielded over 4000 infectious viral particles per cell. Harvesting time, culture media, and concentration of the inducer for the best suspension subclone were further characterized. With these two types of stable cells (pool and subclone), we successfully improved the titer of protease-deleted adenovirus in adherent and suspension cultures and eliminated the need for FBS during the scale-up production. Eight lots of SC-AdV were produced in the best suspension subclone at a scale of 2 to 8.2 L. The viral and infectious particle titers were influenced by the virus backbone and expressed transgene.

Indexed as

AdenoviridaeGenetic VectorsCell LinePeptide HydrolasesPeptide Hydrolasesprotease-deleted adenovirussingle-cycle adenovirus vectorstable cell linesuspension culture

Identifiers

PMID36831286
PMCPMC9954690
OpenAlexW4320919638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.